Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cell>Point
Colorado, United Statescellpointweb.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Cell>Point developed diagnostic radiopharmaceuticals to address unmet needs in cancer and cardiac imaging. Their lead product, 99m-Tc-Ethylenedicysteine-glucosamine (99mTc-EC-DG), achieved Phase 3 status for lung cancer imaging and coronary artery disease diagnostics; comparative studies showed non-inferior performance to standard PET/CT agents (18F-FDG). No commercial launches appear complete; company has faced legal/SEC issues halting activity
- Therapeutic areas
- OncologyInfectious DiseasesCardiovascular
- Modalities
- RadiopharmaceuticalSmall molecule
- Industry
- Medical Imaging
02
Partnerships
Licensed five platform technologies from The University of Texas MD Anderson Cancer Center
Beyond the preview
Go deeper on Cell>Point.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cell>Point.